Nonmyeloablative stem cell transplantation (NST) harnesses the graft-versus-tumor effect while minimizing regimen-related toxicity, and can result in donor chimerism and remission. Acute graft-versus-host disease (GVHD) and infections are major complications after sibling NST. Toxicity of unrelated-donor (UD) NST and the most appropriate GVHD prophylaxis in this setting remain poorly defined. We describe 25 patients who received UD-NST conditioned with fludarabine and cyclophosphamide. The first six patients received cyclosporine (Cs) and mycophenolate mofetil (MMF) (n ¼ 5) or methotrexate (MTX) (n ¼ 1) as GVHD prophylaxis (group 1) and all developed grade III-IV acute GVHD. The next 19 patients received the same conditioning regimen with the addition of alemtuzumab, and all received Cs/MTX post-transplant. Engraftment and donor chimerism were achieved in all but one evaluable patient. In all, 15 patients died: five of six deaths in group 1 were attributable to acute GVHD, while deaths in group 2 were due to infection or progressive disease (P ¼ 0.05). The combination of Cs/MMF is inadequate GVHD prophylaxis for UD-NST. The use of Cs, MTX, and alemtuzumab eliminated severe acute GVHD; its impact on response merits further study. Bone Marrow Transplantation (2005) 35, 921-926.
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The graft-versus-tumor (GVT) effect is important for successful allogeneic SCT and is mediated primarily by donor T-cells. [1] [2] [3] [4] Nonmyeloablative stem cell transplantation (NST) seeks to take advantage of the GVT effect without the toxicity of myeloablative conditioning. NST using HLA-matched related donors results in donor engraftment in 80-100% of patients; about half of these patients experience complete remissions. Grade II-IV acute graftversus-host disease (GVHD) occurs in 20-50% of patients, depending on the type of GVHD prophylaxis, with transplant-related mortality ranging from 7 to 40%.
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The toxicity after myeloablative unrelated-donor (UD) SCT is often higher than after matched sibling SCT, 9 in part due to significantly higher rates of graft failure and GVHD 10, 11 and delayed immune reconstitution. 12 Initial trials reported that UD-NST may also result in higher toxicity than matched sibling NST, largely attributable to high rates of severe acute GVHD, resulting in death in many of these patients. 13, 14 In our experience, the risk of severe acute GVHD was unacceptable using only cyclosporine (Cs) and mycophenolate mofetil (MMF) as GVHD prophylaxis. 14 We therefore added alemtuzumab to our conditioning regimen for subsequent patients. Alemtuzumab (Campath-1 H, Berlex Laboratories, Richmond, CA, USA) is a recombinant humanized antibody to CD52, 15 which effectively depletes both lymphocytes and antigen presenting cells by complement-mediated lysis. 16, 17 In addition to facilitating graft acceptance via host lymphocyte depletion, because of its long half-life, alemtuzumab may also result in in vivo donor T-cell depletion, thus serving as GVHD prophylaxis. Depletion of host antigen-presenting cells (APC) may also limit subsequent GVHD. 18 In other reports, alemtuzumab had resulted in a low incidence of acute GVHD after NST. 19, 20 To better define toxicity and outcomes after UD-NST, we report outcomes from 25 recipients of UD-NST conditioned with fludarabine and cyclophosphamide without (n ¼ 6) or with (n ¼ 19) alemtuzumab at a single institution. The addition of alemtuzumab, with the replacement of MMF with methotrexate (MTX), dramatically reduced the incidence of severe acute GVHD.
Patients and methods
Eligible patients were between 18 and 72 years of age, with a diagnosis of a lymphoproliferative disorder, myeloproliferative or myelodysplastic syndrome, or myeloma which was incurable with standard therapy, and were unable to undergo traditional UD SCT because of advanced age or co-morbid medical conditions including prior autologous transplant. Donors were identified through the National Marrow Donor Program; HLA typing was performed by DNA-SSP. The protocol was approved by the Institutional Review Board of the University of Pennsylvania. All patients provided written informed consent.
Treatment regimen
Group 1 received fludarabine 30 mg/m 2 /day on days À5 to À2 and cyclophosphamide 3 g/m 2 /day on day À2. GVHD prophylaxis consisted of Cs beginning on day À3 for a minimum of 30 days post-transplant, with target trough levels of 200-300 mg/l. The first five patients also received MMF 500 mg twice daily; the sixth patient instead received MTX by intravenous bolus (15 mg/m 2 on day þ 1, followed by 10 mg/m 2 on days þ 3, þ 6, and þ 11). Group 2 received a regimen identical to group 1, except that the conditioning regimen included intravenous alemtuzumab, and all patients in this group received Cs/MTX. A test dose of alemtuzumab 3 mg was given on day À9, followed by 10 mg on day À8 and 30 mg on days À7 to À5 (100 mg total, excluding test dose).
All patients received similar infectious prophylaxis with acyclovir (800 mg by mouth twice daily) through day 28 and either fluconazole or voriconazole. In addition, trimethoprim/sulfamethoxazole was administered for 14 days prior to transplant to prevent Pneumocystis carinii pneumonia. No antibacterial prophylaxis was given, although all patients who developed fever were treated empirically with a fourth-generation cephalosporin as well as other appropriate antibiotics as clinically indicated. Testing for CMV antigenemia was performed weekly until day 100, and ganciclovir was administered when testing was positive.
Clinical end points
Primary end points of the study were grade III-IV acute GVHD and donor hematopoietic cell engraftment. Acute GVHD was graded according to Glucksberg criteria. 21 Chimerism, as determined by peripheral blood samples using informative short tandem repeat polymorphisms, 22, 23 was evaluated beginning at least on day 30 and monthly thereafter. Secondary end points were maximum response, progression-free survival, transplant-related mortality, and overall survival.
Statistical methods
Using STATA 7.0. (Stata Corporation, College Station, TX, USA), patient characteristics were compared with Fisher's exact test or, for patient and donor age, the Wilcoxon rank-sum test.
Onset of grade III-IV acute GVHD and time to neutrophil engraftment were evaluated using the KaplanMeier method and groups were compared with the log-rank test. Median maximum chimerism was compared using the Wilcoxon rank-sum test. Response and cause of death were evaluated with Fisher's exact test. Response was evaluated as a dichotomous variable, with complete or partial remission counted as a response. Unadjusted probabilities of survival, transplant-related mortality, and progression-free survival were estimated with the Kaplan-Meier method and compared using the log-rank test. All P-values are two-sided.
Results

Patient and disease characteristics
Patient characteristics are shown in Table 1 . Other than the use of MMF vs MTX as post-transplant GVHD prophylaxis, there were no significant differences between the two groups. The population as a whole was heavily pretreated, with 19 of 25 patients having received a prior autologous SCT. The six patients without prior autologous SCT had CLL (3), MDS (2), or myelofibrosis (1). Type of disease and pre-transplant disease status were similar between the two groups. The four untreated patients had myelodysplasia (3) or myelofibrosis (1).
End points
Graft-versus-host disease. In group 1, all patients developed severe (grade III-IV) acute GVHD, compared with no patients in group 2 (Po0.01) ( Table 2 ). The median time to onset of acute GVHD was 18.5 days (range 9-45 days). Of note, five of six patients in group 1 developed severe acute GVHD before the initiation of the Cs taper (ie prior to day 30), indicating that the initial planned Cs taper was not responsible for the severity of GVHD. Five of these patients died from complications related to GVHD and/or infection. In group 2, one patient developed grade I GVHD and five patients developed grade II GVHD (all involved skin only and occurred prior to day 100). No patient in group 2 died from complications related to acute GVHD. The probability of developing grade III-IV acute GVHD is depicted in Figure 1 .
Engraftment and chimerism. One patient died prior to chimerism assessment, and one patient with myelodysplasia died at day 21 post-transplant from sepsis, and had not yet engrafted. Only the latter patient was in the alemtuzumab group. Among the 23 evaluable patients, median time to neutrophil engraftment (ANC4500/ml) was 8 days in group 1 and 16 days in group 2 (Po0.01). Median maximum chimerism among patients who were evaluable for engraftment was 99.5% in group 1 (range 68-100%) and 95.5% in group 2 (range 0-100%), and the pace of achieving donor chimerism was similar (Table 3) . In group 1, 4/6 patients had 495% donor chimerism at day 30, and 2/4 evaluable patients had 495% donor chimerism at day 60 and day 100. In group 2, the proportions of patients achieving 495% donor chimerism were: 6/17 patients at day 30, 7/13 evaluable patients at day 60, and 5/13 patients at day 100. An additional three patients at day 100 had between 85 and 95% donor chimerism.
Response and progression-free survival. There were initial responses in all five evaluable patients in group 1, and in 11 of 17 evaluable patients in group 2. Progression-free survival for both groups is depicted in Figure 2 . Owing to the small number of patients and very early deaths seen in group 1, the impact of alemtuzumab on response rates cannot be assessed. Survival. At the time of last follow-up, 12 patients were alive and evaluable for disease status. Five were alive and in CR (two HD and three NHL) and seven were alive with disease. In all, 13 patients have died (Table 2) . In group 1, acute GVHD and/or infection was the cause of death in five of six patients. In group 2, seven patients have died: two from infection, four from progressive disease, and one from regimen-related pulmonary toxicity (P ¼ 0.05 for all causes of death). All infectious deaths were related to bacterial sepsis in the immediate post-transplant period (prior to day 60); one patient who did not receive alemtuzumab developed both Pseudomonas sepsis and invasive aspergillosis. Three of the four fatal infections occurred in patients with prior autologous transplants, and the fourth occurred in a patient with longstanding myelodysplasia and neutropenia. No patient developed CMV disease. There was a marked decrease in transplant-related mortality (Po0.01) and improved overall survival in group 2 (P ¼ 0.04) ( Table 2 ). The median survival in group 1 was 71 days, while the median survival in group 2 has not yet been reached with a median follow-up of 293 days.
Discussion
The addition of alemtuzumab and substitution of MTX for MMF for GVHD prevention markedly reduced the incidence of severe acute GVHD. Although the number of patients treated is small, there were no obvious pretreatment differences between the groups that should have accounted for the different outcomes. Our data strongly suggest that (1) UD-NST conditioned with fludarabine and cyclophosphamide, using Cs/MMF GVHD prophylaxis, results in an unacceptable degree of severe acute GVHD; (2) the addition of alemtuzumab to the conditioning therapy and substitution of MTX for MMF dramatically reduces the incidence of acute GVHD, making UD-NST far safer in this high-risk patient population; and (3) although these changes significantly delay neutrophil engraftment, donor chimerism is achieved in most patients after UD-NST. In recipients of related donor NST, alemtuzumab reduced GVHD compared to previous reports without alemtuzumab: 0-20% of patients developed grade III-IV acute GVHD and 2-10% developed chronic GVHD. 8, 19 One study has compared matched sibling NST in two different centers with and without alemtuzumab, using otherwise identical conditioning regimens. The center that included alemtuzumab reported a significantly lower risk of severe acute GVHD (2.6 vs 13.7%, P ¼ 0.015) and comparable event-free and overall survival. 24 Many, although not all, reports have confirmed that UD-NST is feasible and efficacious, but carries a high risk of severe acute GVHD. 13, 14, 20 Wong et al reported a 20% incidence of grade III-IV acute GVHD in 29 recipients of UD-NST, 18 of whom received antithymocyte globulin (ATG) as part of the conditioning. Acute GVHD accounted for death in five of 11 patients who did not receive ATG. 25 The MD Anderson group also reported a 39% risk of grade III-IV acute GVHD in 40 recipients of UD-NST, 13 while a report from Japan described grade III-IV acute GVHD in 3/11 recipients of UD-NST who did not receive ATG and in 0/9 recipients when ATG was part of the conditioning regimen. 26 The lowest incidence of severe acute GVHD after UD-NST without the use of ATG or alemtuzumab was 10% in 89 patients conditioned with fludarabine and low-dose total body irradiation (TBI) using Cs and MMF for GVHD prophylaxis. 27 It is not clear why there was a relatively low incidence of acute GVHD in this study; it is possible that either the less intensive fludarabine and low-dose TBI conditioning regimen resulted in less tissue damage and hence less acute GVHD, or that the higher dose of MMF used in that study (15 mg/kg twice daily) markedly lowered the risk of GVHD.
Other groups have examined antibody-mediated in vivo T-cell depletion in NST. Ho et al 28 described reducedintensity conditioning consisting of fludarabine, busulfan, and alemtuzumab for 62 patients with myelodysplasia, 38 of whom were recipients of UD grafts. Post-transplant Table 3 Chimerism studies on peripheral blood mononuclear cells Percentages are donor-derived hematopoiesis. a n ¼ Number of patients evaluable. GVHD prophylaxis included only Cs. In this study, 9% of UD-NST recipients developed de novo grade III-IV acute GVHD. Another cohort of patients with lymphoproliferative disorders received BEAM (carmustine, etoposide, cytarabine, melphalan) plus alemtuzumab, followed by UD SCT. 29 Although they report a 17% incidence of grade I-II acute GVHD, and no grade III-IV GVHD, their experience included only eight UD transplants. A 22-patient series describing UD-NST using ATG plus fludarabine and low-dose TBI (200 cGy) demonstrated a 40% risk of grade II-IV acute GVHD despite post-transplant prophylaxis with high doses of a calcineurin inhibitor plus MMF 15 mg/kg twice daily. 30 Thus, it is clear from our experience, combined with these data, that intensive GVHD prophylaxis is required for UD-NST.
Importantly, our GVHD prophylaxis regimen was changed not just by adding alemtuzumab, but also by substituting MTX for MMF. Although it is possible that the significant difference in the risk of acute GVHD between the two groups is due to MTX rather than alemtuzumab, the experience of other centers described above would suggest that Cs/MTX alone results in a significant risk of acute GVHD, while recent reports using in vivo T-cell depletion with ATG or alemtuzumab have lower rates of acute GVHD, comparable to this alemtuzumab-containing regimen. Another possible explanation for our initially high incidence of severe acute GVHD is that our dose of MMF was approximately half of that which is currently used at other centers. Nevertheless, the fact that no patient who received alemtuzumab experienced any grade III or IV acute GVHD is remarkably different from the experience reported by others, even using higher doses of MMF without alemtuzumab. 30 We attribute the delayed engraftment seen in group 2 to the inclusion of MTX in the regimen, although fatal infections did not seem to be related to the use of MTX or to prolonged neutropenia. Significant mucositis was also not observed.
There is concern that alemtuzumab might diminish response rates or increase the risk of relapse by attenuating GVT effects. Our data are limited by small numbers and short follow-up, particularly in group 1. However, the fact that five patients progressed with longer follow-up in the alemtuzumab group suggests that there may be diminished GVT effects with the use of alemtuzumab. Larger studies with longer follow-up are needed to demonstrate whether response and progression-free survival are comparable.
An important additional effect of alemtuzumab is the depletion of host dendritic cells, 31 possibly without delaying reconstitution of donor-derived dendritic cells. 32 Pre-clinical and early clinical data suggest that residual host dendritic cells may play a critical role in the development of GVHD. 18, 33, 34 Thus, it is possible that alemtuzumab exerts its anti-GVHD effect not just by T-cell depletion, but also by depletion of host APC. Recent data in mouse models demonstrate that the GVT effect is dependent on the presence of APC which are allogeneic to T-cells, 35 and thus host APC depletion by alemtuzumab could adversely affect relapse rates. Alemtuzumab's impact on host APCs, and the relative contribution of host APCs to GVHD and to GVT, will be examined in future studies of NST.
Our data suggest that there is a significant risk of severe acute GVHD in UD-NST; intensive GVHD prophylaxis is essential. Further studies to determine the relative importance of T-cell vs antigen-presenting cell depletion, as well as the impact of alemtuzumab on GVT activity, are warranted.
